سعر ريبياكس 12/25 مجم كبسول 2025

Olanzapine 12 mg + fluoxetine 25 mg hard capsules, box of 30 (3 strips) (Rai Pharmaceuticals (Marcyrl), Egypt).

• Acute depressive episodes in Bipolar I Disorder.Population: Adults and children/adolescents 10-17 yearsDailyMed (U.S. National Library of Medicine)
• Treatment-resistant depression (major depressive disorder not responding to 2 adequate antidepressant trials in the current episode).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common in adults (>=5% and twice placebo): sedation, weight increased, appetite increased, dry mouth, fatigue, oedema, tremor, disturbance in attention, blurred vision.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Children and adolescents: sedation, weight increased, appetite increased, tremor, triglycerides increased, hepatic enzymes increased.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Use with MAOIs intended for psychiatric disorders or within 5 weeks of stopping this drug; starting within 14 days of stopping an MAOI; starting in patients on linezolid or IV methylene blue (serotonin syndrome risk).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Concomitant pimozide or thioridazine (QT prolongation; CYP2D6 inhibition).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: increased risk of suicidal thoughts and behaviours in children, adolescents and young adults on antidepressants; monitor closely.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning: increased mortality in elderly patients with dementia-related psychosis; not approved for this use.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Metabolic changes (hyperglycaemia/diabetes, dyslipidaemia, weight gain); serotonin syndrome; neuroleptic malignant syndrome; DRESS; tardive dyskinesia.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• MAOIs (incl. linezolid, IV methylene blue)Contraindicated: risk of serotonin syndrome; observe 14-day and 5-week washout periods.DailyMed (U.S. National Library of Medicine)
• QT-prolonging drugs (e.g. ziprasidone, erythromycin, moxifloxacin, quinidine, amiodarone, sotalol, methadone)Use with caution; pimozide and thioridazine are contraindicated.DailyMed (U.S. National Library of Medicine)

• Available data have not established a drug-associated risk of major birth defects or miscarriage; SSRI exposure near delivery is associated with postpartum haemorrhage risk, and there are risks of PPHN and poor neonatal adaptation with SSRIs and of untreated depression.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Olanzapine, fluoxetine and norfluoxetine are present in human milk; monitor exposed infants for sedation, irritability, poor feeding, poor weight gain and extrapyramidal symptoms.International label, same formulation · DailyMed (U.S. National Library of Medicine)